About vaxcyte inc - PCVX
Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering and Jeff Fairman on November 27, 2013, and is headquartered in San Carlos, CA.
PCVX At a Glance
Vaxcyte, Inc.
825 Industrial Road
San Carlos, California 94070
| Phone | 1-650-837-0111 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -766,628,000.00 | |
| Sector | Health Technology | Employees | 507 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
PCVX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 2.252 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -5.38 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.024 |
PCVX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,512,086.785 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
PCVX Liquidity
| Current Ratio | 7.909 |
| Quick Ratio | 7.909 |
| Cash Ratio | 7.587 |
PCVX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -23.304 |
| Return on Equity | -25.591 |
| Return on Total Capital | -27.35 |
| Return on Invested Capital | -24.859 |
PCVX Capital Structure
| Total Debt to Total Equity | 4.375 |
| Total Debt to Total Capital | 4.191 |
| Total Debt to Total Assets | 3.857 |
| Long-Term Debt to Equity | 4.147 |
| Long-Term Debt to Total Capital | 3.973 |